Urology Times staff

“It certainly seems that we're moving into medical management of advanced diseases,” says J. Christopher Webster, MD, FACS.

“The other aspect of this study that really fascinated us was how patients are getting information about cancer genetic testing,” says Sameer Thakker, MD.

“Almost 1/3 [of telehealth visits] were planned as audio-only, and the healthcare system is no longer going to pay for that. We can use the data from our census to go to Congress and say, 'Hey, you're making a mistake,’” says Amanda North, MD.

Dr. Goldberg discusses his findings on the rates of shared decision-making and PSA testing, which were presented at the NSAUA meeting in Charlotte, North Carolina.

“The biggest question that arose from this is, ‘Why is there such a lack of large familial genetic disorder epidemiological studies?’ says Laura Bukavina, MD, MPH.

“We need to continue to push the field forward, and the way we do that is to evaluate the risk factors and to stratify patients based on their risk factors and their genetic components,” says Laura Bukavina, MD, MPH.

“Not only, as we've shown, does sepsis cost a lot of money, is very morbid, and can lead to mortality, but it's increasing,” says Naeem Bhojani, MD.

"What was surprising to me is that the incidence [of kidney cancer] has leveled off over the past 2 years," says Laura Bukavina, MD, MPH.

“We're trying to see if combining shockwave therapy along with PRP will make an additive impact on the improvement in erectile function in men with erectile dysfunction,” says Ranjith Ramasamy, MD.

“There have been a lot of efforts to increase the diversity of the urologic workforce, and I think the fruits of our labor are starting to show themselves when we look at the residents,” says Amanda North, MD.

“Due to the rarity and poor molecular characterization of nccRCC, there is an underrepresentation in clinical trials evaluating patients with this type of RCC; because of this, patients are often treated with non-tailored therapies,” the researchers wrote.

“From a patient care standpoint, anything that opens the door and makes the patient feel more secure and open is going to lead to better outcomes for them and allow us to serve their needs best,” says Benjamin Lowentritt, MD, FACS.

"The idea that we may have reliable and consistently interpretable tests for these patients is exciting for the future," says Benjamin Lowentritt, MD, FACS.

“There’s always going to be some criticism…but I think we can see what needs to improve and move toward a system that works well for everyone,” says Moben Mirza MD.

In this interview, Ziho Lee, MD, discusses the buccal mucosa graft for urethral and ureteral stricture disease.

“New imaging has rapidly changed the advanced prostate cancer landscape, and all of the existing studies that we have are based on older imaging,” says Dr. Henderson.

“Number 1 to me is going to be an applicant who comes in ready to avail all the opportunity that will be afforded to them during their residency,” says Moben Mirza MD.

“When we think about all the other office-based procedures we do, such as transrectal biopsies and vasectomies that are done in-clinic, I think that technology can play a big role in these," says Dr. Myrga.

"With regards to utilization of buccal mucosa graft in ureteral reconstruction, it's revolutionized the way that we can take care of patients with ureteral strictures, just as buccal mucosa graft revolutionized how urethral reconstruction is being done," says Ziho Lee, MD.

“As the PSMA-PET market for access has grown, the coverage has actually been better than we anticipated when it first launched,” says David Morris, MD.

Silver also outlines an example of a patient who he would treat with high-intensity focused ultrasound.

“PSMA scanning is definitely a game-changer with regard to imaging in advanced prostate cancer in urology,” says Evan R. Goldfischer, MD.

"In a phase 2 clinical trial, we saw that erdafitinib had an objective response rate of around 40% in patients who received prior chemotherapy for their metastatic disease," says Dr. Siefker-Radtke.

“From just a regular business sense, we can’t raise prices to offset some of our supply cost problems,” says David Morris, MD.

"There's 3000 patient trials that are either done or going to be done within the next year or 2 in the BCG-naïve setting, and all of them have systemic therapy," says Joshua J. Meeks, MD, PhD.

"People are starting to retire, and there isn't that much production of urologists every year; there's about 270 that come out for the whole country," says Richard Harris, MD.

"We have more younger members here at the annual meeting than we've ever had before. We want to make that a priority," says Evan R. Goldfischer, MD, MBA, FACS.

"It really is a fun time to be doing urothelial cancer research, as we see patients living longer, with more durable responses, impacting their overall survival and long-term outcomes," says Arlene Siefker-Radtke, MD.

“Don't make assumptions about any patients,” says Diana K. Bowen, MD.

Webster also shares his advice for young urologists entering community practice.